Combining random mutagenesis, structure-guided design and next-generation sequencing to mitigate polyreactivity of an anti-IL-21R antibody

References

• Bhaskar V, Goldfine ID, Bedinger DH, Lau A, Kuan HF, Gross LM, Handa M, Maddux BA, Watson SR, Zhu S, et al. A fully human, allosteric monoclonal antibody that activates the insulin receptor and improves glycemic control. Diabetes. 2012;61(5):1263–13. doi:10.2337/db11-1578.
   PubMed Web of Science ®Google Scholar
• Lim AP, Chan CE, Wong SK, Chan AH, Ooi EE, Hanson BJ. Neutralizing human monoclonal antibody against H5N1 influenza HA selected from a Fab-phage display library. Virol J. 2008;5:130. doi:10.1186/1743-422X-5-130.
   PubMed Web of Science ®Google Scholar
• Kirkham PM, Neri D, Winter G. Towards the design of an antibody that recognises a given protein epitope. J Mol Biol. 1999;285:909–15. doi:10.1006/jmbi.1998.2336.
   PubMed Web of Science ®Google Scholar
• Parsons HL, Earnshaw JC, Wilton J, Johnson KS, Schueler PA, Mahoney W, McCafferty J. Directing phage selections towards specific epitopes. Protein Eng. 1996;9:1043–49. doi:10.1093/protein/9.11.1043.
   PubMedGoogle Scholar
• Fennell BJ, McDonnell B, Tam AS, Chang L, Steven J, Broadbent ID, Gao H, Kieras E, Alley J, Luxenberg D, et al. CDR-restricted engineering of native human scFvs creates highly stable and soluble bifunctional antibodies for subcutaneous delivery. mAbs. 2013;5:882–95. doi:10.4161/mabs.26201.
   PubMed Web of Science ®Google Scholar
• Park H, Kim D, Son E, Shin S, Sa JK, Kim SH, Yoon Y, Nam D-H. Antitumor activity, pharmacokinetics, tumor-homing effect, and hepatotoxicity of a species cross-reactive c-Met antibody. Biochem Biophys Res Commun. 2017;494:409–15. doi:10.1016/j.bbrc.2017.09.061.
   PubMed Web of Science ®Google Scholar
• Pershad K, Pavlovic JD, Graslund S, Nilsson P, Colwill K, Karatt-Vellatt A, Schofield DJ, Dyson MR, Pawson T, Kay BK, et al. Generating a panel of highly specific antibodies to 20 human SH2 domains by phage display. Protein Eng Des Sel. 2010;23(4):279–88. doi:10.1093/protein/gzq003.
   PubMed Web of Science ®Google Scholar
• Datta-Mannan A, Thangaraju A, Leung D, Tang Y, Witcher DR, Lu J, Wroblewski VJ. Balancing charge in the complementarity-determining regions of humanized mAbs without affecting pI reduces non-specific binding and improves the pharmacokinetics. MAbs. 2015;7(3):483–93. doi:10.1080/19420862.2015.1016696.
   PubMed Web of Science ®Google Scholar
• Julian MC, Li L, Garde S, Wilen R, Tessier PM. Efficient affinity maturation of antibody variable domains requires co-selection of compensatory mutations to maintain thermodynamic stability. Sci Rep. 2017;7:45259. doi:10.1038/srep45259.
   PubMed Web of Science ®Google Scholar
• Wu SJ, Luo J, O’Neil KT, Kang J, Lacy ER, Canziani G, Baker A, Huang M, Tang QM, Raju TS, et al. Structure-based engineering of a monoclonal antibody for improved solubility. Protein Eng Des Sel. 2010;23:643–51. doi:10.1093/protein/gzq037.
   PubMed Web of Science ®Google Scholar
• Birtalan S, Zhang Y, Fellouse FA, Shao L, Schaefer G, Sidhu SS. The intrinsic contributions of tyrosine, serine, glycine and arginine to the affinity and specificity of antibodies. J Mol Biol. 2008;377:1518–28. doi:10.1016/j.jmb.2008.01.093.
   PubMed Web of Science ®Google Scholar
• Schoch A, Kettenberger H, Mundigl O, Winter G, Engert J, Heinrich J, Emrich T. Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics. Proc Natl Acad Sci U S A. 2015;112:5997–6002. doi:10.1073/pnas.1408766112.
   PubMed Web of Science ®Google Scholar
• Li B, Tesar D, Boswell CA, Cahaya HS, Wong A, Zhang J, Meng YG, Eigenbrot C, Pantua H, Diao J, et al. Framework selection can influence pharmacokinetics of a humanized therapeutic antibody through differences in molecule charge. MAbs. 2014;6(5):1255–64. doi:10.4161/mabs.29809.
   PubMed Web of Science ®Google Scholar
• Sampei Z, Igawa T, Soeda T, Okuyama-Nishida Y, Moriyama C, Wakabayashi T, Tanaka E, Muto A, Kojima T, Kitazawa T, et al. Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity. PLoS One. 2013;8(2):e57479. doi:10.1371/journal.pone.0057479.
   PubMed Web of Science ®Google Scholar
• Igawa T, Tsunoda H, Tachibana T, Maeda A, Mimoto F, Moriyama C, Nanami M, Sekimori Y, Nabuchi Y, Aso Y, et al. Reduced elimination of IgG antibodies by engineering the variable region. Protein Eng Des Sel. 2010;23(5):385–92. doi:10.1093/protein/gzq009.
   PubMed Web of Science ®Google Scholar
• Hotzel I, Theil F-P, Bernstein LJ, Prabhu S, Deng R, Quintana L, Lutman J, Sibia R, Chan P, Bumbaca D, et al. A strategy for risk mitigation of antibodies with fast clearance. MAbs. 2012;4(6):753–60. doi:10.4161/mabs.22189.
   PubMed Web of Science ®Google Scholar
• Kelly RL, Sun T, Jain T, Caffry I, Yu Y, Cao Y, Lynaugh H, Brown M, Vásquez M, Wittrup KD, et al. High throughput cross-interaction measures for human IgG1 antibodies correlate with clearance rates in mice. MAbs. 2015;7(4):770–77. doi:10.1080/19420862.2015.1043503.
   PubMed Web of Science ®Google Scholar
• Avery LB, Wade J, Wang M, Tam A, King A, Piche-Nicholas N, Kavosi MS, Penn S, Cirelli D, Kurz JC, et al. Establishing in vitro in vivo correlations to screen monoclonal antibodies for physicochemical properties related to favorable human pharmacokinetics. MAbs. 2018;10(2):244–55. doi:10.1080/19420862.2017.1417718.
   PubMed Web of Science ®Google Scholar
• Liu Y, Caffry I, Wu J, Geng SB, Jain T, Sun T, Reid F, Cao Y, Estep P, Yu Y, et al. High-throughput screening for developability during early-stage antibody discovery using self-interaction nanoparticle spectroscopy. mAbs. 2014;6(2):483–92. doi:10.4161/mabs.27431.
   PubMed Web of Science ®Google Scholar
• Kelly RL, Le D, Zhao J, Wittrup KD. Reduction of nonspecificity motifs in synthetic antibody libraries. J Mol Biol. 2018;430:119–30. doi:10.1016/j.jmb.2017.11.008.
   PubMed Web of Science ®Google Scholar
• Hamming OJ, Kang L, Svensson A, Karlsen JL, Rahbek-Nielsen H, Paludan SR, Hjorth SA, Bondensgaard K, Hartmann R. Crystal structure of interleukin-21 receptor (IL-21R) bound to IL-21 reveals that sugar chain interacting with WSXWS motif is integral part of IL-21R. J Biol Chem. 2012;287:9454–60. doi:10.1074/jbc.M111.311084.
   PubMed Web of Science ®Google Scholar
• Vugmeyster Y, Allen S, Szklut P, Bree A, Ryan M, Ma M, Spaulding V, Young D, Guay H, Bloom L, et al. Correlation of pharmacodynamic activity, pharmacokinetics, and anti-product antibody responses to anti-IL-21R antibody therapeutics following IV administration to cynomolgus monkeys. J Transl Med. 2010;8(1):41. doi:10.1186/1479-5876-8-41.
   PubMedGoogle Scholar
• Vugmeyster Y, Guay H, Szklut P, Qian MD, Jin M, Widom A, Spaulding V, Bennett F, Lowe L, Andreyeva T, et al. In vitro potency, pharmacokinetic profiles and pharmacological activity of optimized anti-IL-21R antibodies in a mouse model of lupus. MAbs. 2010;2(3):335–46. doi:10.4161/mabs.2.3.11850.
   PubMed Web of Science ®Google Scholar
• Matlab R2010b. Natick (MA): Mathworks Inc; 2010. p. 2010.
   Google Scholar
• Xu Y, Roach W, Sun T, Jain T, Prinz B, Yu T-Y, Torrey J, Thomas J, Bobrowicz P, Vasquez M, et al. Addressing polyspecificity of antibodies selected from an in vitro yeast presentation system: a FACS-based, high-throughput selection and analytical tool. Protein Eng Des Sel. 2013;26(10):663–70. doi:10.1093/protein/gzt047.
   PubMed Web of Science ®Google Scholar
• Lou J, Marzari R, Verzillo V, Ferrero F, Pak D, Sheng M, Yang C, Sblattero D, Bradbury A. Antibodies in haystacks: how selection strategy influences the outcome of selection from molecular diversity libraries. J Immunol Methods. 2001;253(1–2):233–42. doi:10.1016/S0022-1759(01)00385-4.
   PubMed Web of Science ®Google Scholar
• Sharma VK, Patapoff TW, Kabakoff B, Pai S, Hilario E, Zhang B, Li C, Borisov O, Kelley RF, Chorny I, et al. In silico selection of therapeutic antibodies for development: viscosity, clearance, and chemical stability. Proc Natl Acad Sci U S A. 2014;111(52):18601–06. doi:10.1073/pnas.1421779112.
   PubMed Web of Science ®Google Scholar
• Sormanni P, Aprile FA, Vendruscolo M. The CamSol method of rational design of protein mutants with enhanced solubility. J Mol Biol. 2015;427:478–90. doi:10.1016/j.jmb.2014.09.026.
   PubMed Web of Science ®Google Scholar
• Jensen KK, Andreatta M, Marcatili P, Buus S, Greenbaum JA, Yan Z, Sette A, Peters B, Nielsen M. Improved methods for predicting peptide binding affinity to MHC class II molecules. Immunology. 2018;154:394–406. doi:10.1111/imm.12889.
   PubMed Web of Science ®Google Scholar
• Jawa V, Cousens LP, Awwad M, Wakshull E, Kropshofer H, De Groot AS. T-cell dependent immunogenicity of protein therapeutics: preclinical assessment and mitigation. Clin immunol. 2013;149:534–55. doi:10.1016/j.clim.2013.09.006.
   PubMed Web of Science ®Google Scholar
• Mason DM, Friedensohn S, Weber CR, Jordi C, Wagner B, Meng S, Gainza P, Correia BE, Reddy ST. Deep learning enables therapeutic antibody optimization in mammalian cells by deciphering high-dimensional protein sequence space. bioRxiv. 2019;617860.
   Google Scholar
• Finlay WJ, Cunningham O, Lambert MA, Darmanin-Sheehan A, Liu X, Fennell BJ, Mahon CM, Cummins E, Wade JM, O’Sullivan CM, et al. Affinity maturation of a humanized rat antibody for anti-RAGE therapy: comprehensive mutagenesis reveals a high level of mutational plasticity both inside and outside the complementarity-determining regions. J Mol Biol. 2009;388:541–58. doi:10.1016/j.jmb.2009.03.019.
   PubMed Web of Science ®Google Scholar
• Cummins E, Luxenberg DP, McAleese F, Widom A, Fennell BJ, Darmanin-Sheehan A, Whitters MJ, Bloom L, Gill D, Cunningham O, et al. A simple high-throughput purification method for hit identification in protein screening. J Immunol Methods. 2008;339(1):38–46. doi:10.1016/j.jim.2008.07.016.
   PubMed Web of Science ®Google Scholar
• Pini A, Viti F, Santucci A, Carnemolla B, Zardi L, Neri P, Neri D. Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel. J Biol Chem. 1998;273:21769–76. doi:10.1074/jbc.273.34.21769.
   PubMed Web of Science ®Google Scholar
• Barbas CF 3rd, Bain JD, Hoekstra DM, Lerner RA. Semisynthetic combinatorial antibody libraries: a chemical solution to the diversity problem. Proc Natl Acad Sci U S A. 1992;89:4457–61. doi:10.1073/pnas.89.10.4457.
   PubMed Web of Science ®Google Scholar
• Finlay WJ, Bloom L, Cunningham O. Optimized generation of high-affinity, high-specificity single-chain Fv antibodies from multiantigen immunized chickens. Methods Mol Biol. 2011;681:383–401.
   PubMedGoogle Scholar
• Magoc T, Salzberg SL. FLASH: fast length adjustment of short reads to improve genome assemblies. Bioinformatics. 2011;27:2957–63. doi:10.1093/bioinformatics/btr507.
   PubMed Web of Science ®Google Scholar
• Shugay M, Britanova OV, Merzlyak EM, Turchaninova MA, Mamedov IZ, Tuganbaev TR, Bolotin DA, Staroverov DB, Putintseva EV, Plevova K, et al. Towards error-free profiling of immune repertoires. Nat Methods. 2014;11:653–55. doi:10.1038/nmeth.2960.
   PubMed Web of Science ®Google Scholar
• Sirin S, Apgar JR, Bennett EM, Keating AE. AB-bind: antibody binding mutational database for computational affinity predictions. Protein Sci. 2016;25:393–409. doi:10.1002/pro.2829.
   PubMed Web of Science ®Google Scholar
• Guerois R, Nielsen JE, Serrano L. Predicting changes in the stability of proteins and protein complexes: a study of more than 1000 mutations. J Mol Biol. 2002;320:369–87. doi:10.1016/S0022-2836(02)00442-4.
   PubMed Web of Science ®Google Scholar
• Schymkowitz J, Borg J, Stricher F, Nys R, Rousseau F, Serrano L. The FoldX web server: an online force field. Nucleic Acids Res. 2005;33:W382–8. doi:10.1093/nar/gki387.
   PubMed Web of Science ®Google Scholar